<DOC>
	<DOCNO>NCT01286675</DOCNO>
	<brief_summary>Eltrombopag may improve cell collection available Autologous Stem Cell Transplant ( ASCT ) . The overall goal determine add Eltrombopag standard ASCT increase number blood cell collect reduce number time blood need collect . This study also determine high dose Eltrombopag use without cause serious side effect .</brief_summary>
	<brief_title>Effect Eltrombopag Plus Granulocyte Colony-stimulating Factor ( G-CSF ) Human CD34+ Cell Mobilization Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant ( ASCT )</brief_title>
	<detailed_description>Subjects receive standard treatment autologous stem cell transplant . Subjects assign receive Eltrombopag one three dose level Eltrombopag . Subjects receive oral Eltrombopag day 2-15 treatment .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Multiple myeloma Stable responsive disease least 2 cycle conventional chemotherapy Slated undergo autologous peripheral blood stem cell transplant Normal organ marrow function Myocardial infarction within 6 month treatment Receiving study agent Pregnant breastfeeding Uncontrolled intercurrent illness Evidence active recent history thromboembolic disease Previous history primary platelet disorder bleed disorder History different malignancy unless disease free least 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ASCT</keyword>
	<keyword>G-CSF</keyword>
</DOC>